These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1532555)

  • 1. 5-HT3 receptor antagonists reverse helpless behaviour in rats.
    Martin P; Gozlan H; Puech AJ
    Eur J Pharmacol; 1992 Feb; 212(1):73-8. PubMed ID: 1532555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F.
    Mele PC; McDonough JR; McLean DB; O'Halloran KP
    Eur J Pharmacol; 1992 Aug; 218(2-3):229-36. PubMed ID: 1330594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.
    Adrien J; Tissier MH; Lanfumey L; Haj-Dahmane S; Jolas T; Franc B; Hamon M
    Neuropharmacology; 1992 Jun; 31(6):519-29. PubMed ID: 1407392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist effects at putative central 5-HT4 receptors in rat hippocampus by R(+)- and S(-)-zacopride; no evidence for stereo-selectivity.
    Boddeke HW; Kalkman HO
    Neurosci Lett; 1992 Jan; 134(2):261-3. PubMed ID: 1589153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat.
    Costall B; Domeney AM; Naylor RJ
    Neuroreport; 1990 Sep; 1(1):77-80. PubMed ID: 1966601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An initial three-component pharmacophore for specific serotonin-3 receptor ligands.
    Rizzi JP; Nagel AA; Rosen T; McLean S; Seeger T
    J Med Chem; 1990 Oct; 33(10):2721-5. PubMed ID: 2145434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
    J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.
    Bhandari P; Andrews PL
    Eur J Pharmacol; 1991 Nov; 204(3):273-80. PubMed ID: 1663456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zacopride and BRL 24924 induce an increase in EEG-energy in rats.
    Boddeke HW; Kalkman HO
    Br J Pharmacol; 1990 Oct; 101(2):281-4. PubMed ID: 2257436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.
    Sancilio LF; Pinkus LM; Jackson CB; Munson HR
    Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
    Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural studies on WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety.
    Bill DJ; Fletcher A; Glenn BD; Knight M
    Eur J Pharmacol; 1992 Aug; 218(2-3):327-34. PubMed ID: 1358637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
    Langlois A; Pascaud X; Junien JL; Dahl SG; Rivière PJ
    Eur J Pharmacol; 1996 Dec; 318(1):141-4. PubMed ID: 9007525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron.
    Toral J; Hu W; Critchett D; Solomon AJ; Barrett JE; Sokol PT; Ziai MR
    J Pharm Pharmacol; 1995 Jul; 47(7):618-22. PubMed ID: 8568632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zacopride, a potent 5-HT3 antagonist.
    Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L
    J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.